Newer agents, such as Ravulizumab (a long-acting C5 inhibitor), have eased the burden by reducing infusion frequency from every two weeks to every eight weeks, but the core questions of cost and duration of therapy remain at the forefront of nephrology discourse.
The clinical presentation is a triad of terror: hemolytic anemia, thrombocytopenia, and acute kidney injury. But beneath these vital signs lies a microscopic war. In aHUS, the tiny capillaries of the kidney become a battlefield. Platelets are consumed in a frenzy of clotting, and red blood cells are shattered against the fibrin meshwork of microthrombi—creating the classic "schistocytes" seen on blood smears. It is a thrombotic storm, localized within the microvasculature, suffocating the kidneys from the inside out.
Research identified mutations in genes encoding complement regulatory proteins—most notably CFH (Complement Factor H), CFI , MCP , and C3 itself. In a healthy individual, Factor H acts as a brake pedal, slowing down the alternative complement pathway to prevent it from attacking healthy tissue. In aHUS patients, this brake pedal is broken or missing due to genetic mutations.
Newer agents, such as Ravulizumab (a long-acting C5 inhibitor), have eased the burden by reducing infusion frequency from every two weeks to every eight weeks, but the core questions of cost and duration of therapy remain at the forefront of nephrology discourse.
The clinical presentation is a triad of terror: hemolytic anemia, thrombocytopenia, and acute kidney injury. But beneath these vital signs lies a microscopic war. In aHUS, the tiny capillaries of the kidney become a battlefield. Platelets are consumed in a frenzy of clotting, and red blood cells are shattered against the fibrin meshwork of microthrombi—creating the classic "schistocytes" seen on blood smears. It is a thrombotic storm, localized within the microvasculature, suffocating the kidneys from the inside out.
Research identified mutations in genes encoding complement regulatory proteins—most notably CFH (Complement Factor H), CFI , MCP , and C3 itself. In a healthy individual, Factor H acts as a brake pedal, slowing down the alternative complement pathway to prevent it from attacking healthy tissue. In aHUS patients, this brake pedal is broken or missing due to genetic mutations.
